Evidence That Links Loss of Cyclooxygenase-2 With Increased Asymmetric Dimethylarginine | Zendy

Blerina AhmetajShala | Zendy; Nicholas S. Kirkby | Zendy; Rebecca Knowles | Zendy; Malak Al-Yamani | Zendy; Sarah Ismail Mazi | Zendy; Zhen Wang | Zendy; Arthur Tucker | Zendy; Louise S. Mackenzie | Zendy; Paul C. Armstrong | Zendy; Rolf M. Nüsing | Zendy; James Tomlinson | Zendy; Timothy D. Warner | Zendy; James Leiper | Zendy; Jane A. Mitchell | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evidence That Links Loss of Cyclooxygenase-2 With Increased Asymmetric Dimethylarginine

Author(s) -

Blerina AhmetajShala,

Nicholas S. Kirkby,

Rebecca Knowles,

Malak Al-Yamani,

Sarah Ismail Mazi,

Zhen Wang,

Arthur Tucker,

Louise S. Mackenzie,

Paul C. Armstrong,

Rolf M. Nüsing,

James Tomlinson,

Timothy D. Warner,

James Leiper,

Jane A. Mitchell

Publication year - 2014

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.114.011591

Subject(s) - cyclooxygenase , asymmetric dimethylarginine , nitric oxide synthase , medicine , nitric oxide , endothelial dysfunction , prostacyclin , endocrinology , pharmacology , endothelial nos , arginine , chemistry , enos , biochemistry , enzyme , amino acid

Cardiovascular side effects associated with cyclooxygenase-2 inhibitor drugs dominate clinical concern. Cyclooxygenase-2 is expressed in the renal medulla where inhibition causes fluid retention and increased blood pressure. However, the mechanisms linking cyclooxygenase-2 inhibition and cardiovascular events are unknown and no biomarkers have been identified.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research